Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC)Saadatmand, S., Obdeijn, I-M., Rutgers, E. J., Oosterwijk, J. C., Tollenaar, R. A., Woldringh, G. H., Bergers, E., Verhoef, C., Heijnsdijk, E. A., Hooning, M. J., de Koning, H. J. & Tilanus-Linthorst, M. M., 1-Oct-2015, In : International Journal of Cancer. 137, 7, p. 1729-1738 10 p.
Research output: Contribution to journal › Article › Academic › peer-review
Adding MRI to annual mammography screening improves early breast cancer detection in women with familial risk or BRCA1/2 mutation, but breast cancer specific metastasis free survival (MFS) remains unknown. We compared MFS of patients from the largest prospective MRI Screening Study (MRISC) with 1:1 matched controls. Controls, unscreened if
What's New? Adding MRI to annual mammography screening improves early breast cancer detection in women with familial risk or BRCA1/2 mutation. The impact of MRI screening on metastasis free survival remains unknown, however. For ethical reasons, all of the relevant studies so far have had a non-randomized design. To address this issue, here the authors compare breast cancer patients in the largest prospective MRI Screening Study (MRISC) with controls matched for risk group, year of diagnosis, and age at diagnosis. Annual screening with MRI and mammography improves breast cancer specific metastasis free survival significantly in women with BRCA1 mutation or familial predisposition.
|Number of pages||10|
|Journal||International Journal of Cancer|
|Publication status||Published - 1-Oct-2015|
- BRCA1, BRCA2, breast cancer survival, familial cancer syndromes, screening, HEREDITARY BREAST-CANCER, FOLLOW-UP, RANDOMIZED-TRIALS, MAMMOGRAPHY, CARRIERS, SURVEILLANCE, POPULATION, MASTECTOMY, THERAPY, MULTICENTER